Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.46 |
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.46 |
| ▸ | VEGFA | P15692 | 4/20 | 0.40 |
| ▸ | FLT1 | P17948 | 4/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14319655 | 0.85 | EGLN1 (0.61) | EGLN1EGLN3VEGFAFLT1 | |
| SCHEMBL24405061 | 0.84 | CNR2 (0.43) | CNR2EGLN1EGLN3VEGFAFLT1 | |
| SCHEMBL12534212 | 0.83 | CNR2 (0.44) | CNR2EGLN1EGLN3VEGFAFLT1 | |
| SCHEMBL1921259 | 0.81 | EGLN1 (0.44) | CNR2EGLN1EGLN3VEGFAFLT1 | |
| SCHEMBL14331169 | 0.79 | EGLN1 (0.57) | CNR2EGLN1EGLN3VEGFAFLT1 | |
| SCHEMBL3484941 | 0.78 | EGLN1 (0.58) | CNR2EGLN1EGLN3VEGFAFLT1 | |
| SCHEMBL21116365 | 0.78 | SMPD1 (0.42) | CNR2EGLN1 | |
| SCHEMBL30748264 | 0.77 | CA12 (0.47) | — | |
| SCHEMBL28413248 | 0.77 | CA12 (0.47) | — | |
| SCHEMBL1921669 | 0.77 | EGLN1 (0.68) | CNR2EGLN1EGLN3VEGFAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478615-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240358691-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT COMPANY, LLC (PR) | 2024-10-31 | — | — | US | disclosed |
| US-11883386-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-06-29 | — | — | US | disclosed |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-06-29 | — | — | US | disclosed |
| EP-4095127-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3357911-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-7811595-B2 | such as {[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester; for controlling Peripheral Vascular Disease, Coronary Artery Disease, heart failure, ischemia, and anemia | WARNER CHILCOTT COMPANY, LLC (US) | 2010-10-12 | — | — | US | disclosed |
| US-7811595-B2 | such as {[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester; for controlling Peripheral Vascular Disease, Coronary Artery Disease, heart failure, ischemia, and anemia | WARNER CHILCOTT COMPANY, LLC (US) | 2010-10-12 | — | — | US | disclosed |
| US-7811595-B2 | such as {[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester; for controlling Peripheral Vascular Disease, Coronary Artery Disease, heart failure, ischemia, and anemia | WARNER CHILCOTT COMPANY, LLC (US) | 2010-10-12 | — | — | US | disclosed |
| CN-101506149-A | Prolyl hydroxylase inhibitors and methods of use | PROCTER & GAMBLE (US) | 2009-08-12 | — | — | CN | disclosed |
| EP-2044005-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008002576-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008002576-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | CNR2 2002/4885EGLN1 6/4885EGLN3 2/4885 |
| US-11883386-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | CNR2 2002/4885EGLN1 6/4885EGLN3 2/4885 |
| US-20240358691-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, EGLN2 | CNR2 1871/4885EGLN1 6/4885EGLN3 2/4885 |
| US-12478615-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | CNR2 2002/4885EGLN1 6/4885EGLN3 2/4885 |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | CNR2 2002/4885EGLN1 6/4885EGLN3 2/4885 |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | CNR2 2002/4885EGLN1 6/4885EGLN3 2/4885 |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | CNR2 2002/4885EGLN1 6/4885EGLN3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.